Compare iShares JPMorgan USD Emerging Markets Bond ETF (EMB) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares JPMorgan USD Emerging Markets Bond ETF vs Revvity Inc — how do they compare? iShares JPMorgan USD Emerging Markets Bond ETF trades at $95.55, while Revvity Inc trades at $111 (market cap $12.42B). The key difference: Revvity Inc pays a 0.25% dividend while iShares JPMorgan USD Emerging Markets Bond ETF pays none, and Revvity Inc is trading nearer its 52-week high, iShares JPMorgan USD Emerging Markets Bond ETF nearer its low. Which is the better fit depends on your goals.
| EMB | RVTY | |
|---|---|---|
Sector | Fixed Income | Technology |
52-Week High | $97.74 | $117.75 |
52-Week Low | $91.59 | $82.26 |
Market Cap | — | $12.42B |
Enterprise Value | — | $14.91B |
Dividend Yield | — | 0.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EMB trades at $95.625 with minimal daily movement (+0.06%). Technical indicators show a bearish bias with moving averages signaling sell pressure, though oscillators remain neutral. The ETF has demonstrated stable dividend distributions with recent payouts around $0.40-0.41 per share. Emerging market bond ETFs face increased institutional interest but remain sensitive to Federal Reserve policy and geopolitical risks.
The outlook for EMB hinges on emerging market sovereign debt performance amid shifting Fed rates and global risk appetite. Key opportunities include attractive yields relative to developed markets, while risks center on currency volatility and sovereign default exposure in hard currency bonds. Current technical weakness suggests cautious near-term positioning.
RVTY trades at $111.40, up 0.17% on the day, with a bullish technical signal from moving averages and recent earnings beats. The company maintains stable revenue around $2.9B with an 8.26% net income margin, though its P/E ratio of 53.53 suggests premium valuation. Recent news highlights AI integration advances and FDA clearances, supporting growth initiatives.
Outlook is cautiously optimistic with strong analyst buy ratings (51.72%) and a $111.43 consensus target, but high valuation and margin pressures pose risks. Earnings on August 4, 2026, will be critical for confirming growth trajectory amid competitive and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares JPMorgan USD Emerging Markets Bond ETF
EMB invests in U.S. dollar-denominated sovereign debt from emerging market countries. It provides exposure to government bonds from dozens of nations like Turkey, Mexico, and Brazil, offering a way to seek higher yields and geographic diversification.
Read more on EMB →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
